nodes	percent_of_prediction	percent_of_DWPC	metapath
Etravirine—CYP2C19—Cholecalciferol—psoriasis	0.05	0.0736	CbGbCtD
Etravirine—CYP3A4—Calcitriol—psoriasis	0.0469	0.069	CbGbCtD
Etravirine—CYP2C9—Cholecalciferol—psoriasis	0.0415	0.0612	CbGbCtD
Etravirine—CYP3A4—Methoxsalen—psoriasis	0.0365	0.0537	CbGbCtD
Etravirine—ABCB1—Mycophenolate mofetil—psoriasis	0.0349	0.0515	CbGbCtD
Etravirine—CYP2C19—Prednisone—psoriasis	0.0346	0.051	CbGbCtD
Etravirine—CYP2C19—Cyclosporine—psoriasis	0.0328	0.0483	CbGbCtD
Etravirine—ABCB1—Betamethasone—psoriasis	0.03	0.0441	CbGbCtD
Etravirine—ABCB1—Prednisolone—psoriasis	0.0296	0.0436	CbGbCtD
Etravirine—ABCB1—Hydrocortisone—psoriasis	0.028	0.0413	CbGbCtD
Etravirine—ABCB1—Prednisone—psoriasis	0.0279	0.0411	CbGbCtD
Etravirine—CYP2C9—Cyclosporine—psoriasis	0.0273	0.0402	CbGbCtD
Etravirine—ABCB1—Cyclosporine—psoriasis	0.0265	0.039	CbGbCtD
Etravirine—CYP3A4—Cholecalciferol—psoriasis	0.0242	0.0356	CbGbCtD
Etravirine—CYP2C19—Dexamethasone—psoriasis	0.0216	0.0318	CbGbCtD
Etravirine—CYP3A4—Mycophenolate mofetil—psoriasis	0.0209	0.0308	CbGbCtD
Etravirine—CYP3A4—Triamcinolone—psoriasis	0.0209	0.0308	CbGbCtD
Etravirine—CYP2C9—Dexamethasone—psoriasis	0.018	0.0265	CbGbCtD
Etravirine—CYP3A4—Betamethasone—psoriasis	0.018	0.0264	CbGbCtD
Etravirine—CYP3A4—Prednisolone—psoriasis	0.0177	0.0261	CbGbCtD
Etravirine—ABCB1—Dexamethasone—psoriasis	0.0174	0.0257	CbGbCtD
Etravirine—CYP3A4—Hydrocortisone—psoriasis	0.0168	0.0247	CbGbCtD
Etravirine—CYP3A4—Prednisone—psoriasis	0.0167	0.0246	CbGbCtD
Etravirine—CYP3A4—Cyclosporine—psoriasis	0.0159	0.0234	CbGbCtD
Etravirine—ABCB1—Methotrexate—psoriasis	0.014	0.0206	CbGbCtD
Etravirine—CYP3A4—Dexamethasone—psoriasis	0.0105	0.0154	CbGbCtD
Etravirine—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00123	0.0742	CbGpPWpGaD
Etravirine—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00113	0.0676	CbGpPWpGaD
Etravirine—ABCB4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00111	0.0665	CbGpPWpGaD
Etravirine—ABCB4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000772	0.0464	CbGpPWpGaD
Etravirine—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000765	0.046	CbGpPWpGaD
Etravirine—ABCB4—PPARA activates gene expression—CARM1—psoriasis	0.000725	0.0435	CbGpPWpGaD
Etravirine—ABCB4—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.00071	0.0426	CbGpPWpGaD
Etravirine—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000698	0.0419	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—IL22—psoriasis	0.000599	0.036	CbGpPWpGaD
Etravirine—ABCB4—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000489	0.0294	CbGpPWpGaD
Etravirine—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.00046	0.0276	CbGpPWpGaD
Etravirine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000318	0.0191	CbGpPWpGaD
Etravirine—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000314	0.0188	CbGpPWpGaD
Etravirine—ABCB4—PPARA activates gene expression—PPARG—psoriasis	0.000302	0.0181	CbGpPWpGaD
Etravirine—ABCB4—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	0.000295	0.0177	CbGpPWpGaD
Etravirine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00029	0.0174	CbGpPWpGaD
Etravirine—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000286	0.0172	CbGpPWpGaD
Etravirine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000258	0.0155	CbGpPWpGaD
Etravirine—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000248	0.0149	CbGpPWpGaD
Etravirine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000235	0.0141	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—NDUFA5—psoriasis	0.000209	0.0125	CbGpPWpGaD
Etravirine—ABCB4—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000204	0.0122	CbGpPWpGaD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000195	0.0117	CbGpPWpGaD
Etravirine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000191	0.0115	CbGpPWpGaD
Etravirine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000189	0.0113	CbGpPWpGaD
Etravirine—Ill-defined disorder—Dexamethasone—psoriasis	0.000184	0.000604	CcSEcCtD
Etravirine—Ill-defined disorder—Betamethasone—psoriasis	0.000184	0.000604	CcSEcCtD
Etravirine—Discomfort—Triamcinolone—psoriasis	0.000184	0.000603	CcSEcCtD
Etravirine—Fatigue—Cyclosporine—psoriasis	0.000183	0.000603	CcSEcCtD
Etravirine—Hyperhidrosis—Hydrocortisone—psoriasis	0.000183	0.000601	CcSEcCtD
Etravirine—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000183	0.000601	CcSEcCtD
Etravirine—Constipation—Cyclosporine—psoriasis	0.000182	0.000598	CcSEcCtD
Etravirine—Pain—Cyclosporine—psoriasis	0.000182	0.000598	CcSEcCtD
Etravirine—Dry mouth—Triamcinolone—psoriasis	0.000182	0.000597	CcSEcCtD
Etravirine—Renal failure—Methotrexate—psoriasis	0.000181	0.000596	CcSEcCtD
Etravirine—Angioedema—Dexamethasone—psoriasis	0.000181	0.000595	CcSEcCtD
Etravirine—Angioedema—Betamethasone—psoriasis	0.000181	0.000595	CcSEcCtD
Etravirine—Decreased appetite—Mycophenolate mofetil—psoriasis	0.00018	0.000593	CcSEcCtD
Etravirine—Anorexia—Hydrocortisone—psoriasis	0.00018	0.000593	CcSEcCtD
Etravirine—Diarrhoea—Mycophenolic acid—psoriasis	0.00018	0.000592	CcSEcCtD
Etravirine—Stomatitis—Methotrexate—psoriasis	0.00018	0.000591	CcSEcCtD
Etravirine—Angiopathy—Prednisone—psoriasis	0.00018	0.000591	CcSEcCtD
Etravirine—Conjunctivitis—Methotrexate—psoriasis	0.000179	0.000589	CcSEcCtD
Etravirine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000179	0.000589	CcSEcCtD
Etravirine—Immune system disorder—Prednisone—psoriasis	0.000179	0.000588	CcSEcCtD
Etravirine—Malaise—Betamethasone—psoriasis	0.000179	0.000587	CcSEcCtD
Etravirine—Malaise—Dexamethasone—psoriasis	0.000179	0.000587	CcSEcCtD
Etravirine—Vertigo—Dexamethasone—psoriasis	0.000178	0.000585	CcSEcCtD
Etravirine—Vertigo—Betamethasone—psoriasis	0.000178	0.000585	CcSEcCtD
Etravirine—ABCB4—Metabolism—CYP2S1—psoriasis	0.000178	0.0107	CbGpPWpGaD
Etravirine—Syncope—Dexamethasone—psoriasis	0.000178	0.000584	CcSEcCtD
Etravirine—Syncope—Betamethasone—psoriasis	0.000178	0.000584	CcSEcCtD
Etravirine—Constipation—Mycophenolate mofetil—psoriasis	0.000177	0.000584	CcSEcCtD
Etravirine—Pain—Mycophenolate mofetil—psoriasis	0.000177	0.000584	CcSEcCtD
Etravirine—Infection—Triamcinolone—psoriasis	0.000177	0.000582	CcSEcCtD
Etravirine—Feeling abnormal—Cyclosporine—psoriasis	0.000175	0.000576	CcSEcCtD
Etravirine—Shock—Triamcinolone—psoriasis	0.000175	0.000576	CcSEcCtD
Etravirine—Insomnia—Prednisolone—psoriasis	0.000175	0.000576	CcSEcCtD
Etravirine—Hepatobiliary disease—Methotrexate—psoriasis	0.000174	0.000573	CcSEcCtD
Etravirine—Gastrointestinal pain—Cyclosporine—psoriasis	0.000174	0.000572	CcSEcCtD
Etravirine—Loss of consciousness—Betamethasone—psoriasis	0.000174	0.000572	CcSEcCtD
Etravirine—Loss of consciousness—Dexamethasone—psoriasis	0.000174	0.000572	CcSEcCtD
Etravirine—Dizziness—Mycophenolic acid—psoriasis	0.000174	0.000572	CcSEcCtD
Etravirine—Paraesthesia—Prednisolone—psoriasis	0.000174	0.000572	CcSEcCtD
Etravirine—Mental disorder—Prednisone—psoriasis	0.000173	0.00057	CcSEcCtD
Etravirine—Malnutrition—Prednisone—psoriasis	0.000172	0.000567	CcSEcCtD
Etravirine—Hyperhidrosis—Triamcinolone—psoriasis	0.000172	0.000566	CcSEcCtD
Etravirine—Convulsion—Betamethasone—psoriasis	0.000172	0.000564	CcSEcCtD
Etravirine—Convulsion—Dexamethasone—psoriasis	0.000172	0.000564	CcSEcCtD
Etravirine—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000171	0.000562	CcSEcCtD
Etravirine—Insomnia—Hydrocortisone—psoriasis	0.000171	0.000562	CcSEcCtD
Etravirine—Hypertension—Dexamethasone—psoriasis	0.000171	0.000562	CcSEcCtD
Etravirine—Hypertension—Betamethasone—psoriasis	0.000171	0.000562	CcSEcCtD
Etravirine—Paraesthesia—Hydrocortisone—psoriasis	0.00017	0.000558	CcSEcCtD
Etravirine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.00017	0.000558	CcSEcCtD
Etravirine—Body temperature increased—Cyclosporine—psoriasis	0.000168	0.000553	CcSEcCtD
Etravirine—Abdominal pain—Cyclosporine—psoriasis	0.000168	0.000553	CcSEcCtD
Etravirine—Anxiety—Betamethasone—psoriasis	0.000168	0.000552	CcSEcCtD
Etravirine—Anxiety—Dexamethasone—psoriasis	0.000168	0.000552	CcSEcCtD
Etravirine—Vomiting—Mycophenolic acid—psoriasis	0.000167	0.00055	CcSEcCtD
Etravirine—Discomfort—Betamethasone—psoriasis	0.000167	0.000547	CcSEcCtD
Etravirine—Discomfort—Dexamethasone—psoriasis	0.000167	0.000547	CcSEcCtD
Etravirine—Rash—Mycophenolic acid—psoriasis	0.000166	0.000545	CcSEcCtD
Etravirine—Dermatitis—Mycophenolic acid—psoriasis	0.000166	0.000545	CcSEcCtD
Etravirine—Pain—Prednisolone—psoriasis	0.000166	0.000544	CcSEcCtD
Etravirine—Hepatitis—Methotrexate—psoriasis	0.000165	0.000544	CcSEcCtD
Etravirine—Headache—Mycophenolic acid—psoriasis	0.000165	0.000542	CcSEcCtD
Etravirine—Decreased appetite—Hydrocortisone—psoriasis	0.000164	0.00054	CcSEcCtD
Etravirine—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000164	0.000539	CcSEcCtD
Etravirine—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000164	0.000539	CcSEcCtD
Etravirine—Urinary tract disorder—Methotrexate—psoriasis	0.000163	0.000537	CcSEcCtD
Etravirine—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000163	0.000537	CcSEcCtD
Etravirine—Fatigue—Hydrocortisone—psoriasis	0.000163	0.000536	CcSEcCtD
Etravirine—Vision blurred—Prednisone—psoriasis	0.000162	0.000534	CcSEcCtD
Etravirine—Urethral disorder—Methotrexate—psoriasis	0.000162	0.000533	CcSEcCtD
Etravirine—Pain—Hydrocortisone—psoriasis	0.000162	0.000532	CcSEcCtD
Etravirine—Insomnia—Triamcinolone—psoriasis	0.000161	0.000529	CcSEcCtD
Etravirine—Infection—Betamethasone—psoriasis	0.00016	0.000528	CcSEcCtD
Etravirine—Infection—Dexamethasone—psoriasis	0.00016	0.000528	CcSEcCtD
Etravirine—Ill-defined disorder—Prednisone—psoriasis	0.00016	0.000526	CcSEcCtD
Etravirine—Paraesthesia—Triamcinolone—psoriasis	0.00016	0.000526	CcSEcCtD
Etravirine—Feeling abnormal—Prednisolone—psoriasis	0.00016	0.000525	CcSEcCtD
Etravirine—Anaemia—Prednisone—psoriasis	0.000159	0.000524	CcSEcCtD
Etravirine—Shock—Betamethasone—psoriasis	0.000159	0.000523	CcSEcCtD
Etravirine—Shock—Dexamethasone—psoriasis	0.000159	0.000523	CcSEcCtD
Etravirine—Nervous system disorder—Dexamethasone—psoriasis	0.000158	0.000521	CcSEcCtD
Etravirine—Nervous system disorder—Betamethasone—psoriasis	0.000158	0.000521	CcSEcCtD
Etravirine—Thrombocytopenia—Betamethasone—psoriasis	0.000158	0.00052	CcSEcCtD
Etravirine—Thrombocytopenia—Dexamethasone—psoriasis	0.000158	0.00052	CcSEcCtD
Etravirine—Angioedema—Prednisone—psoriasis	0.000158	0.000518	CcSEcCtD
Etravirine—Hypersensitivity—Cyclosporine—psoriasis	0.000157	0.000515	CcSEcCtD
Etravirine—Erythema multiforme—Methotrexate—psoriasis	0.000156	0.000514	CcSEcCtD
Etravirine—Nausea—Mycophenolic acid—psoriasis	0.000156	0.000514	CcSEcCtD
Etravirine—Hyperhidrosis—Betamethasone—psoriasis	0.000156	0.000513	CcSEcCtD
Etravirine—Hyperhidrosis—Dexamethasone—psoriasis	0.000156	0.000513	CcSEcCtD
Etravirine—Feeling abnormal—Hydrocortisone—psoriasis	0.000156	0.000512	CcSEcCtD
Etravirine—Malaise—Prednisone—psoriasis	0.000155	0.000511	CcSEcCtD
Etravirine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000155	0.0093	CbGpPWpGaD
Etravirine—Vertigo—Prednisone—psoriasis	0.000155	0.000509	CcSEcCtD
Etravirine—Eye disorder—Methotrexate—psoriasis	0.000155	0.000509	CcSEcCtD
Etravirine—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000155	0.000508	CcSEcCtD
Etravirine—Syncope—Prednisone—psoriasis	0.000155	0.000508	CcSEcCtD
Etravirine—Anorexia—Dexamethasone—psoriasis	0.000154	0.000506	CcSEcCtD
Etravirine—Anorexia—Betamethasone—psoriasis	0.000154	0.000506	CcSEcCtD
Etravirine—Cardiac disorder—Methotrexate—psoriasis	0.000154	0.000505	CcSEcCtD
Etravirine—Fatigue—Triamcinolone—psoriasis	0.000154	0.000505	CcSEcCtD
Etravirine—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000153	0.000503	CcSEcCtD
Etravirine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000153	0.00918	CbGpPWpGaD
Etravirine—Asthenia—Cyclosporine—psoriasis	0.000153	0.000502	CcSEcCtD
Etravirine—Pain—Triamcinolone—psoriasis	0.000152	0.000501	CcSEcCtD
Etravirine—Loss of consciousness—Prednisone—psoriasis	0.000152	0.000498	CcSEcCtD
Etravirine—Angiopathy—Methotrexate—psoriasis	0.00015	0.000494	CcSEcCtD
Etravirine—Immune system disorder—Methotrexate—psoriasis	0.000149	0.000491	CcSEcCtD
Etravirine—Abdominal pain—Hydrocortisone—psoriasis	0.000149	0.000491	CcSEcCtD
Etravirine—Body temperature increased—Hydrocortisone—psoriasis	0.000149	0.000491	CcSEcCtD
Etravirine—Convulsion—Prednisone—psoriasis	0.000149	0.000491	CcSEcCtD
Etravirine—Mediastinal disorder—Methotrexate—psoriasis	0.000149	0.00049	CcSEcCtD
Etravirine—Asthenia—Mycophenolate mofetil—psoriasis	0.000149	0.00049	CcSEcCtD
Etravirine—Hypertension—Prednisone—psoriasis	0.000149	0.000489	CcSEcCtD
Etravirine—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000147	0.00884	CbGpPWpGaD
Etravirine—Feeling abnormal—Triamcinolone—psoriasis	0.000147	0.000482	CcSEcCtD
Etravirine—Anxiety—Prednisone—psoriasis	0.000146	0.000481	CcSEcCtD
Etravirine—Insomnia—Betamethasone—psoriasis	0.000146	0.00048	CcSEcCtD
Etravirine—Insomnia—Dexamethasone—psoriasis	0.000146	0.00048	CcSEcCtD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000146	0.000479	CcSEcCtD
Etravirine—Diarrhoea—Cyclosporine—psoriasis	0.000146	0.000479	CcSEcCtD
Etravirine—Paraesthesia—Betamethasone—psoriasis	0.000145	0.000477	CcSEcCtD
Etravirine—Paraesthesia—Dexamethasone—psoriasis	0.000145	0.000477	CcSEcCtD
Etravirine—Discomfort—Prednisone—psoriasis	0.000145	0.000477	CcSEcCtD
Etravirine—Mental disorder—Methotrexate—psoriasis	0.000145	0.000477	CcSEcCtD
Etravirine—Malnutrition—Methotrexate—psoriasis	0.000144	0.000474	CcSEcCtD
Etravirine—Hypersensitivity—Prednisolone—psoriasis	0.000143	0.000469	CcSEcCtD
Etravirine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000142	0.00856	CbGpPWpGaD
Etravirine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000142	0.000467	CcSEcCtD
Etravirine—Body temperature increased—Triamcinolone—psoriasis	0.000141	0.000463	CcSEcCtD
Etravirine—Dizziness—Cyclosporine—psoriasis	0.000141	0.000463	CcSEcCtD
Etravirine—Decreased appetite—Dexamethasone—psoriasis	0.00014	0.000462	CcSEcCtD
Etravirine—Decreased appetite—Betamethasone—psoriasis	0.00014	0.000462	CcSEcCtD
Etravirine—Infection—Prednisone—psoriasis	0.00014	0.00046	CcSEcCtD
Etravirine—Gastrointestinal disorder—Betamethasone—psoriasis	0.000139	0.000459	CcSEcCtD
Etravirine—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000139	0.000459	CcSEcCtD
Etravirine—Hypersensitivity—Hydrocortisone—psoriasis	0.000139	0.000458	CcSEcCtD
Etravirine—Fatigue—Betamethasone—psoriasis	0.000139	0.000458	CcSEcCtD
Etravirine—Fatigue—Dexamethasone—psoriasis	0.000139	0.000458	CcSEcCtD
Etravirine—Shock—Prednisone—psoriasis	0.000138	0.000455	CcSEcCtD
Etravirine—Pain—Betamethasone—psoriasis	0.000138	0.000454	CcSEcCtD
Etravirine—Pain—Dexamethasone—psoriasis	0.000138	0.000454	CcSEcCtD
Etravirine—Nervous system disorder—Prednisone—psoriasis	0.000138	0.000454	CcSEcCtD
Etravirine—Dizziness—Mycophenolate mofetil—psoriasis	0.000137	0.000451	CcSEcCtD
Etravirine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000137	0.00822	CbGpPWpGaD
Etravirine—Skin disorder—Prednisone—psoriasis	0.000137	0.000449	CcSEcCtD
Etravirine—Hyperhidrosis—Prednisone—psoriasis	0.000136	0.000447	CcSEcCtD
Etravirine—Vision blurred—Methotrexate—psoriasis	0.000136	0.000446	CcSEcCtD
Etravirine—Asthenia—Hydrocortisone—psoriasis	0.000136	0.000446	CcSEcCtD
Etravirine—Vomiting—Cyclosporine—psoriasis	0.000135	0.000445	CcSEcCtD
Etravirine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000135	0.00811	CbGpPWpGaD
Etravirine—Rash—Cyclosporine—psoriasis	0.000134	0.000441	CcSEcCtD
Etravirine—Anorexia—Prednisone—psoriasis	0.000134	0.000441	CcSEcCtD
Etravirine—Dermatitis—Cyclosporine—psoriasis	0.000134	0.000441	CcSEcCtD
Etravirine—Ill-defined disorder—Methotrexate—psoriasis	0.000134	0.000439	CcSEcCtD
Etravirine—Headache—Cyclosporine—psoriasis	0.000133	0.000438	CcSEcCtD
Etravirine—Anaemia—Methotrexate—psoriasis	0.000133	0.000438	CcSEcCtD
Etravirine—Feeling abnormal—Dexamethasone—psoriasis	0.000133	0.000438	CcSEcCtD
Etravirine—Feeling abnormal—Betamethasone—psoriasis	0.000133	0.000438	CcSEcCtD
Etravirine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000133	0.00799	CbGpPWpGaD
Etravirine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000133	0.00797	CbGpPWpGaD
Etravirine—Gastrointestinal pain—Betamethasone—psoriasis	0.000132	0.000434	CcSEcCtD
Etravirine—Gastrointestinal pain—Dexamethasone—psoriasis	0.000132	0.000434	CcSEcCtD
Etravirine—Vomiting—Mycophenolate mofetil—psoriasis	0.000132	0.000434	CcSEcCtD
Etravirine—Hypersensitivity—Triamcinolone—psoriasis	0.000131	0.000431	CcSEcCtD
Etravirine—Rash—Mycophenolate mofetil—psoriasis	0.000131	0.00043	CcSEcCtD
Etravirine—Dermatitis—Mycophenolate mofetil—psoriasis	0.000131	0.00043	CcSEcCtD
Etravirine—Headache—Mycophenolate mofetil—psoriasis	0.00013	0.000428	CcSEcCtD
Etravirine—Malaise—Methotrexate—psoriasis	0.00013	0.000427	CcSEcCtD
Etravirine—Vertigo—Methotrexate—psoriasis	0.000129	0.000426	CcSEcCtD
Etravirine—Diarrhoea—Hydrocortisone—psoriasis	0.000129	0.000425	CcSEcCtD
Etravirine—Dizziness—Prednisolone—psoriasis	0.000128	0.000421	CcSEcCtD
Etravirine—Asthenia—Triamcinolone—psoriasis	0.000128	0.00042	CcSEcCtD
Etravirine—Abdominal pain—Dexamethasone—psoriasis	0.000128	0.00042	CcSEcCtD
Etravirine—Abdominal pain—Betamethasone—psoriasis	0.000128	0.00042	CcSEcCtD
Etravirine—Body temperature increased—Dexamethasone—psoriasis	0.000128	0.00042	CcSEcCtD
Etravirine—Body temperature increased—Betamethasone—psoriasis	0.000128	0.00042	CcSEcCtD
Etravirine—Insomnia—Prednisone—psoriasis	0.000127	0.000418	CcSEcCtD
Etravirine—Nausea—Cyclosporine—psoriasis	0.000126	0.000416	CcSEcCtD
Etravirine—Paraesthesia—Prednisone—psoriasis	0.000126	0.000415	CcSEcCtD
Etravirine—Dizziness—Hydrocortisone—psoriasis	0.000125	0.000411	CcSEcCtD
Etravirine—Convulsion—Methotrexate—psoriasis	0.000125	0.00041	CcSEcCtD
Etravirine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000125	0.00749	CbGpPWpGaD
Etravirine—Nausea—Mycophenolate mofetil—psoriasis	0.000123	0.000405	CcSEcCtD
Etravirine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000123	0.00739	CbGpPWpGaD
Etravirine—Decreased appetite—Prednisone—psoriasis	0.000122	0.000402	CcSEcCtD
Etravirine—Rash—Prednisolone—psoriasis	0.000122	0.000401	CcSEcCtD
Etravirine—Dermatitis—Prednisolone—psoriasis	0.000122	0.000401	CcSEcCtD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000122	0.0004	CcSEcCtD
Etravirine—Fatigue—Prednisone—psoriasis	0.000121	0.000399	CcSEcCtD
Etravirine—Headache—Prednisolone—psoriasis	0.000121	0.000399	CcSEcCtD
Etravirine—Discomfort—Methotrexate—psoriasis	0.000121	0.000398	CcSEcCtD
Etravirine—Constipation—Prednisone—psoriasis	0.00012	0.000396	CcSEcCtD
Etravirine—Vomiting—Hydrocortisone—psoriasis	0.00012	0.000395	CcSEcCtD
Etravirine—Rash—Hydrocortisone—psoriasis	0.000119	0.000392	CcSEcCtD
Etravirine—Dermatitis—Hydrocortisone—psoriasis	0.000119	0.000392	CcSEcCtD
Etravirine—Confusional state—Methotrexate—psoriasis	0.000119	0.00039	CcSEcCtD
Etravirine—Headache—Hydrocortisone—psoriasis	0.000118	0.000389	CcSEcCtD
Etravirine—Dizziness—Triamcinolone—psoriasis	0.000118	0.000387	CcSEcCtD
Etravirine—Infection—Methotrexate—psoriasis	0.000117	0.000384	CcSEcCtD
Etravirine—Feeling abnormal—Prednisone—psoriasis	0.000116	0.000381	CcSEcCtD
Etravirine—Asthenia—Betamethasone—psoriasis	0.000116	0.000381	CcSEcCtD
Etravirine—Asthenia—Dexamethasone—psoriasis	0.000116	0.000381	CcSEcCtD
Etravirine—Nervous system disorder—Methotrexate—psoriasis	0.000115	0.000379	CcSEcCtD
Etravirine—Thrombocytopenia—Methotrexate—psoriasis	0.000115	0.000379	CcSEcCtD
Etravirine—Gastrointestinal pain—Prednisone—psoriasis	0.000115	0.000378	CcSEcCtD
Etravirine—Nausea—Prednisolone—psoriasis	0.000115	0.000378	CcSEcCtD
Etravirine—Skin disorder—Methotrexate—psoriasis	0.000114	0.000376	CcSEcCtD
Etravirine—Hyperhidrosis—Methotrexate—psoriasis	0.000114	0.000374	CcSEcCtD
Etravirine—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000114	0.00682	CbGpPWpGaD
Etravirine—Vomiting—Triamcinolone—psoriasis	0.000113	0.000372	CcSEcCtD
Etravirine—ABCB1—Allograft Rejection—IL13—psoriasis	0.000113	0.00678	CbGpPWpGaD
Etravirine—Nausea—Hydrocortisone—psoriasis	0.000112	0.000369	CcSEcCtD
Etravirine—Rash—Triamcinolone—psoriasis	0.000112	0.000369	CcSEcCtD
Etravirine—Dermatitis—Triamcinolone—psoriasis	0.000112	0.000369	CcSEcCtD
Etravirine—Anorexia—Methotrexate—psoriasis	0.000112	0.000368	CcSEcCtD
Etravirine—Headache—Triamcinolone—psoriasis	0.000112	0.000367	CcSEcCtD
Etravirine—Body temperature increased—Prednisone—psoriasis	0.000111	0.000366	CcSEcCtD
Etravirine—Abdominal pain—Prednisone—psoriasis	0.000111	0.000366	CcSEcCtD
Etravirine—Diarrhoea—Dexamethasone—psoriasis	0.000111	0.000363	CcSEcCtD
Etravirine—Diarrhoea—Betamethasone—psoriasis	0.000111	0.000363	CcSEcCtD
Etravirine—Dizziness—Betamethasone—psoriasis	0.000107	0.000351	CcSEcCtD
Etravirine—Dizziness—Dexamethasone—psoriasis	0.000107	0.000351	CcSEcCtD
Etravirine—Insomnia—Methotrexate—psoriasis	0.000106	0.00035	CcSEcCtD
Etravirine—Nausea—Triamcinolone—psoriasis	0.000106	0.000348	CcSEcCtD
Etravirine—Paraesthesia—Methotrexate—psoriasis	0.000106	0.000347	CcSEcCtD
Etravirine—Somnolence—Methotrexate—psoriasis	0.000105	0.000344	CcSEcCtD
Etravirine—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000104	0.00624	CbGpPWpGaD
Etravirine—Hypersensitivity—Prednisone—psoriasis	0.000104	0.000341	CcSEcCtD
Etravirine—Vomiting—Dexamethasone—psoriasis	0.000103	0.000338	CcSEcCtD
Etravirine—Vomiting—Betamethasone—psoriasis	0.000103	0.000338	CcSEcCtD
Etravirine—Decreased appetite—Methotrexate—psoriasis	0.000102	0.000336	CcSEcCtD
Etravirine—Rash—Dexamethasone—psoriasis	0.000102	0.000335	CcSEcCtD
Etravirine—Rash—Betamethasone—psoriasis	0.000102	0.000335	CcSEcCtD
Etravirine—Dermatitis—Dexamethasone—psoriasis	0.000102	0.000335	CcSEcCtD
Etravirine—Dermatitis—Betamethasone—psoriasis	0.000102	0.000335	CcSEcCtD
Etravirine—Gastrointestinal disorder—Methotrexate—psoriasis	0.000102	0.000334	CcSEcCtD
Etravirine—Fatigue—Methotrexate—psoriasis	0.000101	0.000333	CcSEcCtD
Etravirine—Headache—Betamethasone—psoriasis	0.000101	0.000333	CcSEcCtD
Etravirine—Headache—Dexamethasone—psoriasis	0.000101	0.000333	CcSEcCtD
Etravirine—Asthenia—Prednisone—psoriasis	0.000101	0.000332	CcSEcCtD
Etravirine—Pain—Methotrexate—psoriasis	0.000101	0.000331	CcSEcCtD
Etravirine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.93e-05	0.00597	CbGpPWpGaD
Etravirine—Feeling abnormal—Methotrexate—psoriasis	9.69e-05	0.000319	CcSEcCtD
Etravirine—ABCB1—Allograft Rejection—IL12B—psoriasis	9.66e-05	0.0058	CbGpPWpGaD
Etravirine—Diarrhoea—Prednisone—psoriasis	9.63e-05	0.000316	CcSEcCtD
Etravirine—Gastrointestinal pain—Methotrexate—psoriasis	9.61e-05	0.000316	CcSEcCtD
Etravirine—Nausea—Dexamethasone—psoriasis	9.6e-05	0.000316	CcSEcCtD
Etravirine—Nausea—Betamethasone—psoriasis	9.6e-05	0.000316	CcSEcCtD
Etravirine—ABCB1—Allograft Rejection—HLA-E—psoriasis	9.43e-05	0.00566	CbGpPWpGaD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.3e-05	0.00559	CbGpPWpGaD
Etravirine—Dizziness—Prednisone—psoriasis	9.3e-05	0.000306	CcSEcCtD
Etravirine—Abdominal pain—Methotrexate—psoriasis	9.29e-05	0.000306	CcSEcCtD
Etravirine—Body temperature increased—Methotrexate—psoriasis	9.29e-05	0.000306	CcSEcCtD
Etravirine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.28e-05	0.00557	CbGpPWpGaD
Etravirine—Vomiting—Prednisone—psoriasis	8.95e-05	0.000294	CcSEcCtD
Etravirine—Rash—Prednisone—psoriasis	8.87e-05	0.000292	CcSEcCtD
Etravirine—Dermatitis—Prednisone—psoriasis	8.86e-05	0.000291	CcSEcCtD
Etravirine—Headache—Prednisone—psoriasis	8.81e-05	0.00029	CcSEcCtD
Etravirine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.78e-05	0.00527	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—CARM1—psoriasis	8.67e-05	0.00521	CbGpPWpGaD
Etravirine—Hypersensitivity—Methotrexate—psoriasis	8.66e-05	0.000285	CcSEcCtD
Etravirine—Asthenia—Methotrexate—psoriasis	8.44e-05	0.000277	CcSEcCtD
Etravirine—Nausea—Prednisone—psoriasis	8.36e-05	0.000275	CcSEcCtD
Etravirine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	8.23e-05	0.00494	CbGpPWpGaD
Etravirine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	8.12e-05	0.00487	CbGpPWpGaD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.1e-05	0.00487	CbGpPWpGaD
Etravirine—Diarrhoea—Methotrexate—psoriasis	8.04e-05	0.000265	CcSEcCtD
Etravirine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	7.89e-05	0.00474	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	7.8e-05	0.00469	CbGpPWpGaD
Etravirine—Dizziness—Methotrexate—psoriasis	7.78e-05	0.000256	CcSEcCtD
Etravirine—Vomiting—Methotrexate—psoriasis	7.48e-05	0.000246	CcSEcCtD
Etravirine—Rash—Methotrexate—psoriasis	7.41e-05	0.000244	CcSEcCtD
Etravirine—Dermatitis—Methotrexate—psoriasis	7.41e-05	0.000244	CcSEcCtD
Etravirine—Headache—Methotrexate—psoriasis	7.37e-05	0.000242	CcSEcCtD
Etravirine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	7.1e-05	0.00426	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—IL10—psoriasis	7.06e-05	0.00424	CbGpPWpGaD
Etravirine—Nausea—Methotrexate—psoriasis	6.98e-05	0.00023	CcSEcCtD
Etravirine—ABCB1—Allograft Rejection—IL4—psoriasis	6.87e-05	0.00413	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—HLA-B—psoriasis	6.72e-05	0.00403	CbGpPWpGaD
Etravirine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	6.71e-05	0.00403	CbGpPWpGaD
Etravirine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	6.25e-05	0.00375	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—HLA-A—psoriasis	6.22e-05	0.00374	CbGpPWpGaD
Etravirine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.12e-05	0.00368	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	5.69e-05	0.00341	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—CAT—psoriasis	5.33e-05	0.0032	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—IFNG—psoriasis	4.15e-05	0.00249	CbGpPWpGaD
Etravirine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.14e-05	0.00249	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—APOE—psoriasis	4.14e-05	0.00249	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—CXCL8—psoriasis	3.86e-05	0.00232	CbGpPWpGaD
Etravirine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.62e-05	0.00217	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—PPARG—psoriasis	3.61e-05	0.00217	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.18e-05	0.00191	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.14e-05	0.00188	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—NDUFA5—psoriasis	2.75e-05	0.00165	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—TNF—psoriasis	2.69e-05	0.00161	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—NDUFA5—psoriasis	2.69e-05	0.00161	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.67e-05	0.0016	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.57e-05	0.00154	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—NDUFA5—psoriasis	2.51e-05	0.00151	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.5e-05	0.0015	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.38e-05	0.00143	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—CYP2S1—psoriasis	2.34e-05	0.00141	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.34e-05	0.00141	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—CYP2S1—psoriasis	2.28e-05	0.00137	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—CYP2S1—psoriasis	2.13e-05	0.00128	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.77e-05	0.00106	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.71e-05	0.00102	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.66e-05	0.000994	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.55e-05	0.000929	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.41e-05	0.000845	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.33e-05	0.000796	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.23e-05	0.000737	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.17e-05	0.000702	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—CARM1—psoriasis	1.14e-05	0.000686	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.12e-05	0.000672	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—CARM1—psoriasis	1.12e-05	0.00067	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.07e-05	0.000642	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—CARM1—psoriasis	1.04e-05	0.000626	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.74e-06	0.000585	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—CAT—psoriasis	7.03e-06	0.000422	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—CARM1—psoriasis	6.87e-06	0.000413	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—CAT—psoriasis	6.86e-06	0.000412	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—CAT—psoriasis	6.41e-06	0.000385	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—APOE—psoriasis	5.46e-06	0.000328	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—APOE—psoriasis	5.33e-06	0.00032	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—APOE—psoriasis	4.98e-06	0.000299	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PPARG—psoriasis	4.76e-06	0.000286	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PPARG—psoriasis	4.64e-06	0.000279	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PPARG—psoriasis	4.34e-06	0.000261	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—CAT—psoriasis	4.23e-06	0.000254	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—APOE—psoriasis	3.28e-06	0.000197	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PPARG—psoriasis	2.86e-06	0.000172	CbGpPWpGaD
